Please login to the form below

Not currently logged in
Email:
Password:

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Blind man's buff

Blind man's buff

In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.

Latest news

More from news
Approximately 23 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Market shaping demands behaviour change Market shaping demands behaviour change

    In fact, a 2019 study conducted by the German HTA organisation IQWiG concluded that they deem two-thirds of new innovations reaching the market today offer limited or no additional value

  • The gold standard of scientific evidence The gold standard of scientific evidence

    PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.

  • Digital disruption Digital disruption

    best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical

  • The price is right? The price is right?

    IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.

More from intelligence
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....